Posted Date : 03rd Jun, 2023
Publishing in UGC-approved journals offers several advantages, includi...
Posted Date : 03rd Jun, 2023
UGC-approved journals refer to the scholarly journals that have been a...
Posted Date : 09th Sep, 2022
The University of Pune is going to update the ugc care listed journals...
Posted Date : 09th Sep, 2022
IJARESM Publication have various tie ups with many Conference/Seminar ...
Posted Date : 07th Mar, 2022
Call For Papers : LokSanwad Foundation Aurangabad, Maharashtra One Day...
Review Article on Atypical Antipsychotics in the Treatment of Schizophrenia
Author Name : S. Srivalli Mounika, B. Sagara Sandhya Rani, L. Rama Chandra Reddy, Dr. D. Dhachinamoorthy
ABSTRACT Schizophrenia is characterized by Positive, negative, organizational, cognitive, and mood symptoms. Antipsychotics are the mainstay of the pharmacological treatment of schizophrenia. Treatment-resistant schizophrenia patients are estimated to number between 25% and 33%; negative symptoms (such as impaired thinking, social disengagement, and affect loss) and side effects, particularly extrapyramidal symptoms (EPS), are only little improved by traditional antipsychotics. Conventional antipsychotics are not an ideal long-term treatment option for schizophrenia due to these disadvantages. At minimum, atypical pharmaceuticals are just as effective as conventional medications like haloperidol. However, there are greater adverse effects than with conventional drugs. Clozapine, for example, has a significant risk of serious blood abnormalities that need special attention; in addition, compared to other drugs, it commonly causes uncomfortable tiredness and increased salivation. The selection of an antipsychotic drug should be based on the patient's preferences, response and side effects, medical history, risk factors, and history of adherence, with the side effect profile serving as a key criterion